UCB Bets on Focus, Not Diversification
In contrast to some Big Pharmas, mid-sized UCB has shifted from a diversified to a very focused business model. That means it's relying heavily on commercial success for its three newest drugs. If the new products take off, UCB could by 2012 be delivering stronger earnings growth than its more diversified peers, just as some of them begin to face the worst of their patent cliffs. But it has little room to maneuver if even one of these disappoints.
You may also be interested in...
UCB gains rights to Synosia's potential Parkinson's disease therapies in deal that could be worth $725 million in milestones
Facing a raft of patent expiries, AstraZeneca pays richly for Rigel's Phase II oral RA candidate.
Company will buy Mepha for roughly $590 million in cash to double the size of its international business and diversify its business mix.